People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Biotechnology, Other Technology, Pharma, Other, Computers
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals, LLC | — | Biotechnology | Series C | $142.9M | $2.1B | 2015 |
| Clear Labs, Inc. | — | Biotechnology | Series C | $135.8M | $218.3M | 2018 |
| Mach Acquisition, Inc. | — | Other Technology | Series A | $10.0M | $33.6M | 2025 |
| Monitored Therapeutics, Inc. | — | Pharma | Series A | $8.5M | $82.3M | 2020 |
| MPJ Management, LLC | — | Other | Seed | $3.5M | $27.9M | 2014 |
| NRX Pharmaceuticals, Inc. | — | Biotechnology | Seed | $3.5M | $12.3M | 2025 |
| Growth Geeks Inc. | — | Computers | Pre-Seed | $100K | $5.1M | 2015 |
Michael Taylor at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Taylor on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gaurav Garg | 1 | 12 |
| Mark Shary | 1 | 11 |
| Patrick Flynn | 1 | 8 |
| Mostafa Ronaghi | 1 | 8 |
| Greg Yap | 1 | 8 |
| Michael Abrams | 1 | 6 |
| Chaim Hurvitz | 1 | 6 |
| Farzad Naimi | 1 | 5 |
| Kazutaka Ohno | 1 | 4 |
| Ming Fang | 1 | 4 |
| Brian Hogan | 1 | 4 |
| Jonathan Javitt | 1 | 3 |
| Patricia L. Allen | 1 | 3 |
| Thomas F. Kelly | 1 | 3 |
| Edward J. Benz, Jr. | 1 | 3 |
| John A. Martin | 1 | 3 |
| Christopher J Morl | 1 | 3 |
| Rhett Schildroth | 1 | 2 |
| Richard Murdock | 1 | 2 |
| Colin Hurd | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.